Introduction
Breast cancer is a heterogeneous disease with multiple classification systems. 1 Recently added molecular classification can better explain the breast tumour molecular biology than other classifications. 2, 3 It can warn the clinicians regarding the prognosis of breast cancer of a particular molecular type that emphasizes on its clinical care. The original molecular classification has been derived from thorough investigations on fresh frozen tissue that is based upon molecular expression of ER, PR, Her-2 and Ki67. Five major subtypes are commonly extracted in this regard that is associated with several molecular alterations and distinct clinical outcome including therapeutic response. These molecular subtypes are luminal A, luminal B, Her-2 enriched, triple negative breast cancer (TNBC) and basal/normal like breast cancer. 3 Besides there may be some others additional subgroups like interferon-enriched, 4 molecular apocrine 5 and so on.
Triple negative breast cancer (TNBC) may be defined as tumours that lack expression of estrogen receptor (ER), progesterone receptor (PR) and Her-2. 6 This subtype may encompass other molecular subtypes of breast cancer. These include claudin like tumours, which are reported to be enriched with cells that have properties exactly similar to those of stem cells and to have features of epithelial to mesenchymal transition, the interferon rich subgroups. This subgroup encompasses tumours with a considerably better prognosis. The normal breast like subgroup may be an artifact i.e. it may comprise samples enriched with a disproportionately high content of stromal and normal cells. 7 The dreadful statistics of South-East Asia showed that 76,000 women die of breast cancer every year. 8 In Bangladesh, there is no recognized and useful cancer registry at national level except the domestic registry of National Institute of Cancer Research and Hospital (NICRH), Mohakhali, Dhaka. It is estimated that an annual new breast cancer case burden is not less than 30,000. 9 Simultaneously, we are far behind the usefulness of molecular subtypes in case of prognosis and clinical care of breast cancer patients. National Institute of Cancer Research and Hospital is a well equipped super specialty centre where maximum bulk of breast cancer patients of the country attends to seek one stop medical services. For this reason, this study aimed at to observe the incidence and clinical presentation as well as histopathological features of TNBC patients.
Materials and method
Patients who were diagnosed with breast cancer and underwent curative surgery in the department of Surgical Oncology at National Institute of Cancer Research & Hospital (NICRH), Mohakhali, Dhaka, Bangladesh, from January 2015 to December 2016 were included in the study. The inclusion criteria were i) with or without axillary lymph node metastasis on pathological examination and ii) available results of immunohistochemistry (IHC) for HRs and HER-2/neu. The exclusion criteria were i) patients who received neoadjuvant chemotherapy and ii) patients who received adjuvant trastuzumab. We evaluated each patient's clinicopathological features, molecular biomarkers, clinical outcome and follow up findings.
The patients were invited to the OPD at three-month intervals during the first year following adjuvant treatment and in six-month intervals during the next year. During each visit, physical examinations were carried out and the patients were asked to undergo blood analyses (complete blood count, routine biochemical tests, and tumour markers), mammography and/or USG of both breasts and axilla, abdominal USG and additional examinations including bone profile and bone scintigraphy, if indicated and all of the patients were monitored for recurrence/metastasis. 
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The study protocol was approved by the Institutional Review Board (IRB) of NICRH.
Statistical Analysis
The comparisons of clinicopathological variables and patterns of relapse between TN breast cancer and non-TN breast cancer were made using 
Results

Discussion
Breast cancer has been recognized as a multifaceted disease which is composed of distinct biological subtypes with diverse natural history. It may be presented as a varied spectrum of clinico-pathological and molecular features. These features have distinct therapeutic and prognostic uses. 12 Our study confirmed those features of breast cancer once again.
We have collected data from 138 patients who fulfilled all the eligibility criteria. Majority cases (38.4%) belonged to 41-50 years which was subsequently followed by 36.2% cases of 31-40 years age group. The mean age of the participants was 43.20±9.69 years. Our findings were almost nearer to the report of Tiwari et al. 13 where they claimed the mean age of their respondents was 47.76±11.08 years. They found 37.1% patients in 41-50 years age group which was 38.4% in our counterpart.
Geographic variation in breast cancer incidence can be attributed to racial and genetic differences, cultural differences, as well as environmental exposures that vary worldwide. 14 It is not only the headache for developed world but also a threatening terror for the least developed world at present. Especially urban females are mostly affected in developing countries due to westernization of lifestyle. 15 Age at marriage, reduced breast feeding and increased junk food consumption may be the attributable factors for developing breast cancer in relatively early age than before. 16 This study observed 64.49% breast cancer in left side which was supported by the report of Ambroise et al. 17 who reported 59.2% in this regard. This study observed that the commonest anatomical site of breast cancer was upper and outer quadrant (52.9%) which was in accordance with Naeem et al. 18 Painless lump (87.5%) was the highly frequent clinical presentation followed by nipple discharge in 8.31% and these results were supported by the findings of Sofi et al. 19 where they claimed that 85.3% and 7.3% of their cases had painless lump and nipple discharge respectively.
Majority cases of this study revealed tumour size as 2-5cm (65.2%) which was subsequently followed by >5cm sized tumour (27.53%). Patel et al. 20 in their study presented the similar findings.
Infiltrating duct cell carcinoma was the sole morphological category where grade-II was the highest (86.95%) which was followed by grade-I (20.45%) tumour. This study found no lobular and inflammatory breast cancer. Hussain et al. noticed the similar findings. 21 All invasive epithelial tumours were graded here according to the Modified Blood Richardsm Grading. 22 Recently, a refined assessment of hormone receptors in breast carcinoma has become mandatory to choose therapeutic agents according to the recommendations and guideline for adjuvant systemic therapy of early breast cancer proposed by the international consensus panel during the St. Gallen conference in 2005. 23 The guidelines proposed 3 disease responsiveness groups. Firstly, endocrine responsive; secondly endocrine response uncertain and finally, endocrine nonresponsive. Immunohistochemistry is the method of choice to detect and quantify estrogen receptor (ER) and progesterone receptor (PR). Immunohistochemistry is preferred because of its relative simplicity, low cost, speed of performance, application to small samples, precise identification of reactive elements, simple method of fixation and storage, ability to be applied to archival material and better ability to predict response to adjuvant endocrine therapy owing to validation studies of ER and PR. 24, 25 Breast cancer mortality was evident as decreased in case of positive ER/PR status which is associated with various demographic factors and clinical tumour characteristics. 26 Likewise, lower recurrence is evident following breast conservation surgery. 27 This study showed the incidence of luminal A, luminal B, TNBC, Her-2 enriched and others as 27.53%, 23.18%, 27.53%, 18.84% and 2.89% respectively. There were 4 global molecular subtypes out of 8 possible subtypes commonly used by the researches. 27 The independent prognostic and predictive role of PR expression irrespective of ER expression has become a topic of great dispute as demonstrated by the report from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant trial. It is a large global trial comparing the efficacy of tamoxifen with that of aromatase inhibitor anastrazole. This trial revealed that the patients with ER+/PR+ tumour had a lower recurrence rate than those with ER+/PRtumours. 28 The same study also observes that the patients with ER+/PR-tumours respond nearly as well as anastrazole as those with ER+/PR+ tumours suggests that the ER signaling pathway is functional in many ER+/PR-tumours, consistent with the popular fact that the PR gene is regulated by the estrogen pathway. 28 As it is yet to be very common to use microarray analysis in our perspective, we have utilized the immunohistochemistry based molecular subtyping. There is substantial variation in ER results both in intralaboratory and interlaboratory perspective because of fixation, antigen retrieval and staining methods may vary from laboratory to laboratory. 29 Likewise, substantial discrepancy among Her-2 results from same specimen in different laboratories has also been reported. 30 In this study, luminal A and TNBC are the most prevalent molecular subtypes that claimed 27.53% of total sample size each. Almost similar findings regarding luminal A was observed in the reports by Hao et al. and interestingly, higher figure were observed in previous Western and Indian Studies. 31 Fan et al. reported the normal like molecular subtype as the least common. 32 Their report can be matched in our aspect as 2.89% cases were identified as other variety where normal like is also a category.
In this study, 28.94% cases of TNBC manifested grade-III histopathological status whereas 5.26% each was observed in case of luminal A and luminal B. Among 120 grade-II cases, 34(28.33%) were luminal A which was mostly prevalent. TNBC is usually associated with more aggressive histopathological features. Our findings confirmed the statement again.
The study revealed significant differences among the association of different molecular subtypes and histopathological grading (p=<0.05).
Conclusion
Clinicopathologically it was assumed that TNBC was aggressive than any other variety from the point of view of grade-III. On the contrary, luminal A was a little more aggressive in grade-II. Axillary lymphadenopathy was almost common in all the varieties. So, it may be concluded here that TNBC is more aggressive though maximum cases in our centre present in advanced stage of any subtype.
